Director and 10% Owner Choo Chee Kong Buys $300K More of CytoMed Therapeutics
GDTC sits 46% above its 52-week low of $0.68.
Summary
Director and 10% owner Choo Chee Kong purchased $300,000 of CytoMed Therapeutics shares at $1.50, a 52% premium to the current $0.99 price, adding to his June purchase of $128,778.
Key Events · Ownership and Investor Activity · GDTC
-
Insider Buys $300K at Premium
Choo Chee Kong purchased 200,000 shares for $300,000 at $1.50 per share, a 52% premium to the current $0.99 price.
-
Follows $128K June Purchase
This adds to a $128,778 open-market purchase in June, bringing total recent buying to over $428,000.
-
Transaction Represents 2.6% of Market Cap
The $300,000 purchase equals 2.6% of the company's $11.7 million market cap, a significant commitment for a nano-cap stock.
-
Director and 10% Owner
As both a director and 10% owner, Choo Chee Kong has deep insight into the company's prospects.
Analysis · GDTC · Life Sciences
Choo Chee Kong, a director and 10% owner, bought another $300,000 worth of shares on the open market at $1.50 per share. This follows a $128,778 purchase in June, bringing his total recent buying to over $428,000. The stock currently trades at $0.99, meaning he paid a 52% premium to today's price. For a nano-cap company with a market cap of just $11.7 million, this level of insider buying is a strong signal of conviction from someone with deep knowledge of the business.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 35.4% of the 1144 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.40%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GDTC was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.7M. The 52-week trading range was $0.68 to $3.68. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.